Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
---|
Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
---|
Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
---|
On Wednesday, dermatology drug developer Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) released preliminary results from Part 2 of its Phase 2 trial of VP-315 for basal cell carcinoma.
The Phase 2 trial is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety and tolerability, pharmacokinetics, and efficacy of VP-315 when administered intratumorally to adults with biopsy-proven basal cell carcinoma.
The study enrolled 92 adult subjects. The Part 2 preliminary results are based on 93 confirmed basal cell carcinoma lesions treated during the Phase 2 trial’s Part 2.
However, for histologic reduction in tumor size and overall reduction in tumor size, data from three of the 93 lesions are pending.
The key preliminary Part 2 results were:
The company expects genomic and T-cell (immune response) data in the first quarter of 2025 and plans to request an End-of-Phase 2 meeting with the FDA in the first half of 2025 to determine the next steps for developing VP-315 for treating basal cell carcinoma.
As of June 30, 2024, Verrica had cash and cash equivalents of $31.9 million, expected to support planned operations into the first quarter of 2025.
Price Action: At the last check on Wednesday, VRCA stock was down 24.10% at $4.01.
Read Next:
Posted In: VRCA